These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 18925524

  • 1. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
    Christidou F, Bamichas G, Galaktidou G, Fragidis S, Gionanlis L, Frangia T, Bischiniotis T, Sombolos K.
    Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
    [Abstract] [Full Text] [Related]

  • 2. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C, Temiz A, Yeniçerioğlu Y, Calişkan S, Celik A, Sifil A, Onvural B, Camsari T.
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study.
    Klingel R, Schwarting A, Lotz J, Eckert M, Hohmann V, Hafner G.
    Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423
    [Abstract] [Full Text] [Related]

  • 4. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
    Naumnik B, Pawlak K, Mys'liwiec M.
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
    [Abstract] [Full Text] [Related]

  • 5. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study.
    Naumnik B, Pawlak K, Myśliwiec M.
    Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290
    [Abstract] [Full Text] [Related]

  • 6. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-beta 1 during haemodialysis: a cross-over study.
    Naumnik B, Borawski J, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1690-6. PubMed ID: 17389624
    [Abstract] [Full Text] [Related]

  • 7. Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.
    Rydzewska-Rosołowska A, Borawski J, Myśliwiec M.
    Ren Fail; 2009 Jun; 31(9):791-7. PubMed ID: 19925286
    [Abstract] [Full Text] [Related]

  • 8. The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis.
    Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK, Georgoulis IE, Natse TA.
    Hemodial Int; 2009 Jan; 13(1):43-7. PubMed ID: 19210277
    [Abstract] [Full Text] [Related]

  • 9. [Blood serum hepatocyte growth factor in children with chronic renal failure treated with CAPD and HD].
    Szprynger K, Szczepańska M, Morawiec-Knysak A, Dyduch A.
    Pol Merkur Lekarski; 2000 Apr; 8(46):270-1. PubMed ID: 10897645
    [Abstract] [Full Text] [Related]

  • 10. Effect of unfractionated and low-molecular-weight heparin on OPG, sRANKL, and von Willebrand factor concentrations during hemodialysis.
    Klejna K, Naumnik B, Koc-Żórawska E, Myśliwiec M.
    Clin Appl Thromb Hemost; 2014 May; 20(4):433-41. PubMed ID: 23104956
    [Abstract] [Full Text] [Related]

  • 11. Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: A cross-over study.
    Naumnik B, Pawlak K, Myśliwiec M.
    Cytokine; 2007 Nov; 40(2):98-104. PubMed ID: 17920287
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
    Brunet P, Simon N, Opris A, Faure V, Lorec-Penet AM, Portugal H, Dussol B, Berland Y.
    Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
    [Abstract] [Full Text] [Related]

  • 13. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels.
    Barril G, Bartolomé J, Sanz P, Buoncristiani E, Traver JA, Selgas R, Buoncristiani U, Castillo I, Quiroga JA, Carreño V.
    J Med Virol; 2010 May; 82(5):763-7. PubMed ID: 20336716
    [Abstract] [Full Text] [Related]

  • 14. Acute kidney injury: effect of hemodialysis membrane on Hgf and recovery of renal function.
    Libetta C, Esposito P, Sepe V, Rampino T, Zucchi M, Canevari M, Dal Canton A.
    Clin Biochem; 2013 Jan; 46(1-2):103-8. PubMed ID: 23099196
    [Abstract] [Full Text] [Related]

  • 15. Effect of hemodiafiltration on pregnancy-associated plasma protein A (PAPP-A) and related parameters.
    Kalousová M, Hodková M, Dusilová-Sulková S, Uhrová J, Tesar V, Zima T.
    Ren Fail; 2006 Jan; 28(8):715-21. PubMed ID: 17162432
    [Abstract] [Full Text] [Related]

  • 16. Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study.
    Naumnik B, Rydzewska-Rosołowska A, Myśliwiec M.
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):480-6. PubMed ID: 20682597
    [Abstract] [Full Text] [Related]

  • 17. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J, Galajda P, Ivanková J, Hollý P, Rozborilová E, Kubisz P.
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
    [Abstract] [Full Text] [Related]

  • 18. Expression of hepatocyte growth factor in chronic hepatitis: effect of hemodialysis.
    Bilezikçi B, Demirhan B, Ozdemir N, Elsürer R.
    Ren Fail; 2006 Oct; 28(7):557-60. PubMed ID: 17050238
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P, Ortiz M, Ortega O, Rodríguez I, Seijas V, Carreño A, Oliet A, Vigil A.
    Nefrologia; 2007 Oct; 27(1):46-52. PubMed ID: 17402879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.